[Ioversol 300 and iopamidol 300 in "whole body" computed tomography. A double-blind clinical trial].
The authors compared ioversol 300 to iopamidol 300 by double blind study in patients undergoing enhanced computed body tomography. There was no significant difference in clinical tolerance and efficacy between the two products. Only minor reactions were recorded in both groups. Contrast media were not considered to be responsible for the poor diagnostic quality of a few explorations. Ioversol 300 appears as a well tolerated and effective contrast medium for computed body tomography.
Chagnaud
C
C
Service Central de Radiologie Adultes, Groupe Hospitalier de la Timone, Marseille.
Moulin
G
G
Delannoy
L
L
Gaubert
J Y
JY
Haddad
D
D
Bartoli
J M
JM
Kasbarian
M
M
D000328:Adult; D017544:Aortic Aneurysm, Abdominal / Q000000981:diagnostic imaging; D001162:Arteriosclerosis Obliterans / Q000000981:diagnostic imaging; D003287:Contrast Media; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007479:Iopamidol / Q000009:adverse effects; D007674:Kidney Diseases / Q000000981:diagnostic imaging; D008297:Male; D009369:Neoplasms / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed / Q000379:methods*; D014283:Triiodobenzoic Acids / Q000009:adverse effects; D014916:Whole-Body Irradiation
D003287:Contrast Media; D014283:Triiodobenzoic Acids; D007479:Iopamidol; C054871:ioversol
Ioversol 300 et iopamidol 300 en tomodensitométrie "corps-entier". Essai clinique en double insu.